Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:33:13.926Z.
Consensus retrieved: 2026-10-06T14:28:36.140Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:33:13.926Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7269c43ec051f04bc9b25698fa87f96476c1bd81d443a59abbb4ab2a9593cf8e
Forward PE Ratio (N/A) = Dated Quote Price ($4.07) / Consensus Forward EPS ($-6.62)
FORWARD PE RATIO
N/A
NeuroSense Therapeutics Ltd.
Market Cap
$7.19M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| NeuroSense Therapeutics Ltd. (NRSN) | $7.19M | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.19M | N/A |
| Longeveron Inc. (LGVN)vs › | $7.15M | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.12M | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.04M | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.46M | N/A |
| Exicure, Inc. (XCUR)vs › | $6.88M | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.64M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.07, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-6.62 | $-8.00 – $-4.45 | 2 | n/m |
| 2027-12-31 | $-10.31 | $-14.37 – $-6.24 | 2 | n/m |
| 2028-12-31 | $-7.58 | $-11.96 – $-3.20 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
